Literature DB >> 2819928

Risk of rehospitalization of psychotic patients. A 6-year follow-up investigation using the survival approach.

R Laessle, H Pfister, H U Wittchen.   

Abstract

Risk of rehospitalization was investigated in 100 former psychiatric inpatients with ICD-9 diagnoses of schizophrenia, schizoaffective and affective psychosis in a 6- to 7-year interval following discharge. Subtype of disorder, aftercare characteristics, previous course of illness and specific sociodemographic factors were hypothesized to predict the probability of readmissions to a hospital. For time-related statistical analyses the survival approach and proportional hazards model were used. The risk of rehospitalization varies considerably between the diagnostic subgroups studied, depending on the length of the observation period chosen. Schizophrenics had the highest risk (after 3 years 66%, 6 years 80%), followed by schizoaffective patients (58 and 65%) and affective psychosis patients (41 and 58%). Aftercare in a short defined period after discharge from the hospital reduced significantly the risk of readmission for patients with an affective psychosis and patients who were married. Former rehospitalization increases the risk of a readmission. Severity of psychopathological features had only minor predictive value.

Entities:  

Mesh:

Year:  1987        PMID: 2819928     DOI: 10.1159/000284479

Source DB:  PubMed          Journal:  Psychopathology        ISSN: 0254-4962            Impact factor:   1.944


  3 in total

Review 1.  Multifacility utilization by the chronically mentally ill in the Department of Veterans Affairs.

Authors:  P W Durance; T B Gibson; M L Davis-Sacks; R K Homan
Journal:  J Ment Health Adm       Date:  1992

2.  High risk factors for rehospitalization within six months.

Authors:  R Walker; D Minor-Schork; R Bloch; J Esinhart
Journal:  Psychiatr Q       Date:  1996

Review 3.  Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics.

Authors:  John G Csernansky; Emily K Schuchart
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.